drugset / Trial / NCT02629562
Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects
RandomizedCrossoverTriple-blindTreatment
Summary
Multi-centre, double-blind, randomised, 2-way cross-over study to investigate the PK and PD of B12019 as compared to Neulasta® administered as a single subcutaneous (s.c.) dose in healthy male subjects. B12019 or Neulasta will be administered by s.c. injection.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
Indications
No indication recorded.